Spiteri Cornish Kurt, Lois Noemi, Scott Neil, Burr Jennifer, Cook Jonathan, Boachie Charles, Tadayoni Ramin, la Cour Morten, Christensen Ulrik, Kwok Alvin
Ophthalmology Department, Grampian University Hospitals NHS Trust, Aberdeen, UK.
Cochrane Database Syst Rev. 2013 Jun 5(6):CD009306. doi: 10.1002/14651858.CD009306.pub2.
Several observational studies have suggested the potential benefit of internal limiting membrane (ILM) peeling to treat idiopathic full-thickness macular hole (FTMH). However, no strong evidence is available on the potential benefit(s) of this surgical manoeuvre and uncertainty remains among vitreoretinal surgeons about the indication for peeling the ILM, whether to use it in all cases or in long-standing and/or larger holes.
To determine whether ILM peeling improves anatomical and functional outcomes of macular hole surgery compared with the no-peeling technique and to investigate the impact of different parameters such as presenting vision, stage/size of the hole and duration of symptoms in the success of the surgery.
We searched the Cochrane Central Register of Controlled Trials (CENTRAL) which contains the Cochrane Eyes and Vision Group Trials Register (The Cochrane Library 2013, Issue 2), Ovid MEDLINE, Ovid MEDLINE In-Process and Other Non-Indexed Citations, Ovid MEDLINE Daily, Ovid OLDMEDLINE, (January 1950 to February 2013), EMBASE (January 1980 to February 2013), Latin American and Caribbean Literature on Health Sciences (LILACS) (January 1982 to February 2013), the metaRegister of Controlled Trials (mRCT) (www.controlled-trials.com), ClinicalTrials.gov (www.clinicaltrials.gov) and the WHO International Clinical Trials Registry Platform (ICTRP) (www.who.int/ictrp/search/en). We searched the reference lists of included studies for any additional studies not identified by the electronic searches. We did not use any date or language restrictions in the electronic searches for trials. We last searched the electronic databases on 28 February 2013.We searched reference lists of the studies included in the review for information about other studies on ILM peeling in macular hole surgery. We searched Proceedings for the following conferences up to February 2013: American Academy of Ophthalmology (AAO), Annual Meeting of the American Society of Retina Specialists (ASRS), Annual Meeting of the Retina Society, Congress of the Asia-Pacific Academy of Ophthalmology (APAO), European Association for Vision and Eye Research (EVER) Annual Congress, European Vitreoretinal Society (EVRS) Annual Meeting, Association for Research in Vision and Ophthalmology (ARVO) Meeting, International Vitreoretinal Meeting, and World Ophthalmology Congress.
Only randomised controlled trials (RCTs) comparing ILM peeling with the no-peeling counterpart were included.
Two review authors (KSC and NL) independently assessed the titles and abstracts of all RCTs identified by electronic and manual searches.We obtained Individual patient data (IPD) from three of the four identified eligible trials. The fourth identified RCT had only been published in abstract form and no IPD were available; we included data from this published abstract for one outcome (macular hole closure).The primary outcome was distance visual acuity at six months. Secondary outcomes included distance and near visual acuity at three and 12 months postoperatively, near visual acuity at six months postoperatively, primary (after a single surgery) and final (following more than one surgery) macular hole closure, need for additional surgical interventions, vision-related quality of life and intraoperative and postoperative complications.We performed meta-analysis using standard techniques (the Mantel-Haenszel odds ratio (OR) for binary outcomes, mean difference (MD) for continuous outcomes) using a fixed-effect model. For two outcomes we also used the IPD to perform adjusted analyses using regression methods.
We identified and included four RCTs; these were conducted in Denmark, France, Hong Kong and the United Kingdom/Republic of Ireland and randomised 47, 80, 49 and 141 participants respectively.There was no evidence of a difference in the primary outcome (distance visual acuity at six months), nor in distance visual acuity at 12 months between randomised groups. However, there was evidence of improved best corrected distance visual acuity in the ILM peeling group at three months (WMD -0.09, 95% CI -0.17 to -0.02). We found no evidence for a difference in near vision between groups at any of the time points investigated.Overall, more participants in the ILM peeling group than in the no-peeling group had primary macular hole closure (OR 9.27, 95% CI 4.98 to 17.24); this held true when results were stratified by the stage of the macular hole. There was also evidence that those in the ILM peeling group were more likely to have final macular hole closure (OR 3.99, 95% CI 1.63 to 9.75). Fewer participants required further surgery in the ILM peeling group than in the no-peeling group (OR 0.11, 95% CI: 0.05 to 0.23).Rates of intraoperative and postoperative complications were similar in both groups.Based on the results of one study, there was no evidence that total VFQ-25 or EQ-5D scores differed between the groups at six months. Based on this same study, ILM peeling is highly likely to be cost-effective.
AUTHORS' CONCLUSIONS: Although we found no evidence of a benefit of ILM peeling in terms of the primary outcome (visual acuity at six months), ILM peeling appears to be superior to its no-peeling counterpart as it offers more favourable cost effectiveness by increasing the likelihood of primary anatomical closure and subsequently decreasing the likelihood of further surgery, with no differences in unwanted side-effects compared with no peeling.
多项观察性研究提示内界膜(ILM)剥除术治疗特发性全层黄斑裂孔(FTMH)可能有益。然而,关于这一手术操作潜在益处的有力证据尚不充分,玻璃体视网膜外科医生对于ILM剥除的指征仍存疑问,即该操作是否适用于所有病例,还是仅适用于病程较长和/或裂孔较大的病例。
确定与不进行ILM剥除的技术相比,ILM剥除术是否能改善黄斑裂孔手术的解剖和功能结局,并研究不同参数(如初始视力、裂孔分期/大小及症状持续时间)对手术成功率的影响。
我们检索了Cochrane对照试验中心注册库(CENTRAL,其中包含Cochrane眼科和视觉组试验注册库,2013年第2期《Cochrane图书馆》)、Ovid MEDLINE、Ovid MEDLINE在研及其他未索引文献、Ovid MEDLINE每日更新、Ovid OLDMEDLINE(1950年1月至2013年2月)、EMBASE(1980年1月至2013年2月)、拉丁美洲和加勒比地区健康科学文献数据库(LILACS,1982年1月至2013年2月)、对照试验元注册库(mRCT,www.controlled-trials.com)、ClinicalTrials.gov(www.clinicaltrials.gov)以及世界卫生组织国际临床试验注册平台(ICTRP,www.who.int/ictrp/search/en)。我们还检索了纳入研究的参考文献列表,以查找电子检索未识别出的其他研究。电子检索试验时未设置任何日期或语言限制。我们最后一次检索电子数据库的时间为2013年2月28日。我们检索了本综述纳入研究的参考文献列表,以获取关于黄斑裂孔手术中ILM剥除的其他研究信息。我们检索了截至2013年2月的以下会议论文集:美国眼科学会(AAO)、美国视网膜专家协会年会(ASRS)、视网膜协会年会、亚太眼科学会大会(APAO)、欧洲视觉与眼研究协会(EVER)年会、欧洲玻璃体视网膜学会(EVRS)年会、视觉与眼研究协会(ARVO)会议、国际玻璃体视网膜会议以及世界眼科大会。
仅纳入比较ILM剥除术与不进行ILM剥除术的随机对照试验(RCT)。
两位综述作者(KSC和NL)独立评估通过电子检索和手工检索识别出的所有RCT的标题和摘要。我们从四项已识别的合格试验中的三项获取了个体患者数据(IPD)。第四项已识别的RCT仅以摘要形式发表,无法获取IPD;我们纳入了该已发表摘要中一项结局(黄斑裂孔闭合)的数据。主要结局为术后6个月的远视力。次要结局包括术后3个月和12个月的远视力和近视力、术后6个月的近视力、初次(单次手术后)和最终(多次手术后)黄斑裂孔闭合情况、是否需要额外的手术干预、与视力相关的生活质量以及术中及术后并发症。我们采用标准技术(二分类结局采用Mantel-Haenszel比值比(OR),连续性结局采用均数差(MD))并使用固定效应模型进行Meta分析。对于两项结局,我们还使用IPD通过回归方法进行调整分析。
我们识别并纳入了四项RCT;这些试验分别在丹麦、法国、中国香港以及英国/爱尔兰共和国进行,分别随机分配了47、80、49和141名参与者。随机分组的两组之间在主要结局(术后6个月的远视力)以及术后12个月的远视力方面均无差异。然而,有证据表明ILM剥除术组在术后3个月时最佳矫正远视力有所改善(加权均数差 -0.09,95%可信区间 -0.17至 -0.02)。在任何所研究的时间点,两组之间近视力均无差异。总体而言,ILM剥除术组初次黄斑裂孔闭合的参与者多于不进行ILM剥除术组(OR 9.27,95%可信区间4.98至17.24);按黄斑裂孔分期分层后结果依然如此。也有证据表明ILM剥除术组更有可能实现最终黄斑裂孔闭合(OR 3.99,95%可信区间1.63至9.75)。ILM剥除术组需要进一步手术的参与者少于不进行ILM剥除术组(OR 0.11,95%可信区间:0.05至0.23)。两组术中及术后并发症发生率相似。基于一项研究的结果,没有证据表明两组在术后6个月时总的VFQ-25或EQ-5D评分存在差异。基于同一研究,ILM剥除术极有可能具有成本效益。
尽管我们未发现ILM剥除术在主要结局(术后六个月视力)方面有益的证据,但ILM剥除术似乎优于不进行ILM剥除术,因为它通过提高初次解剖闭合的可能性并随后降低进一步手术的可能性,提供了更有利的成本效益,且与不进行ILM剥除术相比,不良副作用并无差异。